K. Otsubo

发表

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

K. Goto, K. Nishio, Y. Nakanishi, 2019, The oncologist.

Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.

Y. Nakanishi, T. Yoshizumi, S. Buti, 2022, European journal of cancer.

Anticancer drug treatment for advanced lung cancer with interstitial lung disease.

N. Hamada, Y. Nakanishi, I. Okamoto, 2018, Respiratory investigation.

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer.

Y. Nakanishi, I. Okamoto, K. Otsubo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Rationale and Design for J‐SONIC: A Randomized Study of Carboplatin Plus Nab‐paclitaxel With or Without Nintedanib for Advanced Non–Small‐cell Lung Cancer With Idiopathic Pulmonary Fibrosis

M. Kusumoto, M. Ando, Y. Kondoh, 2018, Clinical lung cancer.

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

S. Ikeda, N. Yamamoto, J. Tanizaki, 2021, JTO clinical and research reports.

A juvenile case of pulmonary lymphangitic carcinomatosis caused by sigmoid colon cancer with a component of micropapillary carcinoma.

N. Nakashima, H. Koto, K. Otsubo, 2011, Internal medicine.

MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation

T. Sasaki, K. Nakao, K. Mimori, 2017, Oncogene.

Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor.

S. Anai, Y. Nakanishi, T. Koga, 2012, Internal medicine.

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Y. Nakanishi, I. Okamoto, M. Mori, 2022, BMC cancer.

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.

S. Anai, Y. Nakanishi, I. Okamoto, 2018, Lung cancer.

Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.

N. Hamada, Y. Nakanishi, Koichiro Matsumoto, 2020, International immunology.

Genetic Pro ﬁ ling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

K. Goto, K. Nishio, Y. Nakanishi, 2019 .

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade

Y. Oda, N. Hamada, Y. Nakanishi, 2018, Oncotarget.

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer

Koji Inoue, K. Otsubo, Y. Tsuchiya-Kawano, 2020, Thoracic cancer.

Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2017, Oncotarget.

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy

S. Takamori, M. Shimokawa, K. Takada, 2021, ESMO open.

PICT1 expression is a poor prognostic factor in non-small cell lung cancer

Y. Nakanishi, T. Koga, A. Suzuki, 2014, Oncoscience.

Capturing the mammalian Hippo: Elucidating its role in cancer

K. Mimori, A. Suzuki, T. Maehama, 2013, Cancer science.

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2018, Lung cancer.

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

H. Yoshida, S. Ikeda, N. Yamamoto, 2021, Cancer science.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer

T. Mushiroda, K. Tsuchihashi, H. Saya, 2017, Cancer science.

Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

Y. Nakanishi, I. Okamoto, S. Takamori, 2021, International journal of cancer.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

T. Ohira, K. Nishio, K. Azuma, 2020, Cancer.

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.

Y. Nakanishi, I. Okamoto, H. Kohrogi, 2016, Lung cancer.

Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2020, Cancer science.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Y. Oda, S. Anai, Y. Nakanishi, 2018, Lung cancer.

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab.

Y. Nakanishi, I. Okamoto, K. Otsubo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer

Y. Nakanishi, G. Toyokawa, I. Okamoto, 2020, Thoracic cancer.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

M. Kusumoto, M. Ando, Y. Kondoh, 2022, European Respiratory Journal.

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2019, Clinical lung cancer.

Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission

Y. Nakanishi, M. Shimokawa, Hironori Mikumo, 2021, BMC Infectious Diseases.

Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib

N. Hamada, Y. Nakanishi, K. Takayama, 2015, Investigational New Drugs.

Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.

Y. Nakanishi, S. Masuda, I. Okamoto, 2019, Lung cancer.

P2.03a-056 Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: KTOSG Trial 1301: Topic: Clinical Trials

Y. Nakanishi, I. Okamoto, H. Kohrogi, 2017 .

Vascular-Parenchymal Crosstalk Promotes Lung Fibrosis Through BMPR2 Signaling.

N. Kaminski, G. Paré, S. Keshavjee, 2023, American journal of respiratory and critical care medicine.